Cargando…

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Detalles Bibliográficos
Autores principales:	Mao, Xianhua, Mak, Lung Yi, Seto, Wai-Kay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366787/ https://www.ncbi.nlm.nih.gov/pubmed/37254487 http://dx.doi.org/10.3350/cmh.2023.0173

Ejemplares similares

Screening strategy for non-alcoholic fatty liver disease
por: Zhang, Saisai, et al.
Publicado: (2023)

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies
por: Seto, Wai-Kay
Publicado: (2019)

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2010)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022)

Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment
por: De Siervi, Silvia, et al.
Publicado: (2023)

The role of different viral biomarkers on the management of chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
por: Cheung, Ka Shing, et al.
Publicado: (2022)

The use of transient elastography in the management of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2011)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2011)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2019)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

The latest global burden of liver cancer: A past and present threat
por: Oh, Joo Hyun, et al.
Publicado: (2023)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
por: Mak, Lung-Yi, et al.
Publicado: (2023)

The growing burden of non-alcoholic fatty liver disease on mortality
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
por: Lam, Lok-Ka, et al.
Publicado: (2023)

Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
por: Kan, Karin, et al.
Publicado: (2023)

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
por: Oh, Joo Hyun, et al.
Publicado: (2023)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
por: Liu, Lei, et al.
Publicado: (2022)

Prediction of Mortality in Chronic Liver Disease Using Non-hepatic Comorbidities: No SI of Relief as Yet
por: Kaplan, David E.
Publicado: (2016)

Chronic liver disease: Global perspectives and future challenges to delivering quality health care
por: Seto, Wai-Kay, et al.
Publicado: (2021)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

Hepatic inflammation: an important target for biomarker development in nonalcoholic fatty liver disease
por: Khan, Hiba, et al.
Publicado: (2023)

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
por: Song, Byeong Geun, et al.
Publicado: (2023)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
por: Xu, Nan, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Curing Fatty Liver with Oxysterols?
por: Uehara, Kahealani, et al.
Publicado: (2022)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6vsvdt69ku5b88veds6na5m891